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Introduction
Cytochrome P450 2J2 (CYP2J2) is the only member of the human CYP2J subfamily known for its role in metabolizing arachidonic acid to physiologically important epoxides. Among the CYP2 family, the mRNA levels of CYP2J2 and CYP2C9 were found highly variable in human hearts, while CYP2C8 mRNA was measured in lower abundance (Delozier et al., 2007) . Moreover, Delozier et al., found that CYP2J2 mRNA levels in the heart was approximately 10 times higher than CYP2C9 or CYP2C8.
Besides high expression in the heart tissue, CYP2J2 is present in other tissues as well (Wu et al., 1996) . Based on mRNA levels, the abundance of this enzyme is greatest in the small intestine >heart > skeletal muscles > kidney > salivary glands >lungs and > liver. CYP2J2 in the liver constitutes 1-2% of total P450 content which is similar to the small intestine (1.4% of total P450 content) (Paine et al., 2006) . CYP2J2 is mostly known for its role as the major human arachidonic acid epoxygenase in the heart and various other tissues. In addition to its endogenous role, CYP2J2 also plays a role in drug metabolism. A number of anti-histamine drugs were identified as substrates of CYP2J2 including terfenadine, ebastine and astemizole (Matsumoto and Yamazoe, 2001; Hashizume et al., 2002; Matsumoto et al., 2002; Liu et al., 2006) . In fact, CYP2J2 was shown to be the enzyme responsible for the first pass metabolism of ebastine. However, the overall importance of CYP2J2 in drug metabolism and toxicity has not been established and a broad evaluation of potential substrates for CYP2J2 has not yet been conducted to understand the role, if any, this isoform plays in overall drug metabolism. Because CYP2J2 is predominately expressed (based on DMD30270 mRNA) in the small intestine and heart, the importance of this isoform in drug metabolism may be appreciably underestimated as liver is the predominate tissue typically used in drug research to profile CYPs and to estimate their contribution to the metabolism of new drug candidates.
In this study, the substrate diversity of CYP2J2 is investigated by evaluating 139 marketed drugs from different therapeutic classes. Mass spectral analysis was used to determine the loss of parent compound with time when incubated with recombinant CYP2J2. The substrates metabolized by CYP2J2 were then confirmed by metabolite identification using mass spectral analysis. Moreover, albendazole and amiodarone Michael-Menten derived intrinsic clearance (Cl INT, ) were determine in different in vitro expression systems, human liver microsomes and human intestinal microsomes to further characterize CYP2J2 activity.
Material and Methods
Chemicals. Compounds (Table 1 ) used for CYP2J2 substrate assessment, furafylline, sulfaphenazole, quinidine, ketoconazole, methanol, buspirone, potassium phosphate (monobasic and dibasic), NADPH , glucose-6-phosphate, NADP + , glucose-6-phosphate dehydrogenase and magnesium chloride were purchased from Sigma-Aldrich (St. Louis, MO). Montelukast was purchased from Cayman Chemicals (Ann Arbor, MI).
Benzylnirvanol, N-desethyl amiodarone and albendazole sulfoxide were synthesized at Pfizer Global Research and Development (PGRD), La Jolla Ca. CYP2J2 and CYP3A4 recombinant enzyme (Supersomes ® ) and pooled human liver microsomes and pooled human intestinal microsomes were purchased from BD Gentest (Woburn, MA).
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CYP2J2 Supersomes ® Incubations. Assays were performed on the Beckman Biomek FX system (Beckman Coulter, Inc., Fullerton, CA). Recombinant CYP2J2 incubations contained substrate (1 μM, final organic 0.01% DMSO, 0.6% acetonitrile), 100 pmol/mL recombinant CYP2J2 and 2 mM NADPH in a final volume of 200 µL of 100 mM potassium phosphate buffer, pH 7.4. After a 10 min pre-incubation period at 37 °C, reactions were initiated with the addition of NADPH. Samples (25 µL aliquots) were removed at 0, 5, 10, 20, 30 and 45 min and quenched with 75 µL of cold methanol containing 0.1 µM buspirone (internal standard). Samples were then centrifuged at 3000 rpm (Beckman-Coulter GH3.8A rotor) for 15 minutes. A 50 µL aliquot of supernatant was transferred to a clean 96 shallow well plate and combined with 50 µl Milli-Q water, mixed and placed on LC-MS/MS for analysis. All incubations were performed in triplicate and compounds metabolized by CYP2J2 were confirmed by conducting triplicate experiments on three separate occasions.
Metabolite Identification of CYP2J2 Substrates.
All incubations (total volume 1.0 mL) were conducted at 37 °C for 45 min in 100 mM potassium phosphate buffer (pH 7.4) containing magnesium chloride (10 mM), recombinant CYP2J2 Supersomes® (0.17 mg/mL protein) and NADPH (2 mM).
Reactions were initiated by addition of substrate (15 μM) after preincubation of the reaction mixture for 3 min at 37 °C. Insert Table 2 here
The peak area ratio of the analyte to the internal standard was determined for each injection and used to measure substrate depletion. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 5 min after sample injection.
Mass spectrometric analyses were performed on a ThermoFinnigan Deca XP ion trap mass spectrometer, which was interfaced to an Agilent HP-1100 HPLC system (Agilent Technologies, Palo Alto, CA) and equipped with an electrospray ionization source. The values for ESI were as follows: capillary temperature 270 °C; spray voltage 4.0 kV; capillary voltage 4.0 V; sheath gas flow rate 90 and auxillary gas flow rate 30.
The mass spectrometer was operated in a positive ion mode with data-dependent scanning. The ions were monitored over a full mass range of m/z 125-1000. For a full scan, the automatic gain control was set at 5.0 x 10 8 , maximum ion time was 100 ms and the number of microscans was set at 3. For MS n scanning, the automatic gain control 1.0
x 10 8 , maximum ion time was 400 ms and the number of microscans was set at 2. For data dependent scanning, the default charge-state was 1, default isolation width was 3.0 and the normalized collision energy was 40 V. The injection volume was 20 μL. Multiple reaction monitoring was used to monitor the compounds. Table 3 lists the ionization mode, m/z transitions and retention times for albendazole, amiodarone and their metabolites. The peak area ratio of the analyte to the internal standard (buspirone) was determined for each injection and used to measure substrate depletion.
Michaelis-Menten
Insert Table 3 here
CYP2J2 Homology Model:
The three dimensional model of the CYP2J2 structure was generated based on the crystal structures of CYP2B4 (PDB file 1PO5A), CYP2C8 (PDB file 1PQ2B) and CYP2A6 (PDB file 1Z10D). These enzymes were chosen to model the CYP2J2 structure because they belong to the same CYP2 subfamily and were free of internal mutations or Blundell, 1993) and a homology model was generated using a combination of molecular dynamics, simulated annealing and the restraints based upon the known structures and the alignment. A more detailed description is available at http:// salilab.org/modeller/tutorial.
The homology model was evaluated for unfavorable bond angles and bond lengths and determined to be structurally reasonable based upon Ramachandran plots.
Data Analysis:
In the determination of the in vitro t 1/2 , the analyte/ISTD peak area ratios were converted to percentage drug remaining, using the T = 0 peak area ratio value as 100%. The slope (-k) of the linear regression from log percentage remaining versus incubation time was Data modeling were carried out using GraphPad Prism (version 5.01), GraphPad Software (La Jolla, CA).
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Results
Recombinant CYP2J2 Metabolism of Various Compounds
One hundred thirty nine drugs from different therapeutic classes (Table 1) were evaluated for their potential to undergo metabolism by CYP2J2. Astemizole and terfenadine served as positive controls since both have been characterized previously as substrates for CYP2J2 (Hashizume et al., 2002; Matsumoto et al., 2002; Matsumoto et al., 2003; Lafite et al., 2006) . The metabolism of terfenadine by recombinant CYP2J2 is three times faster than astemizole, with Cl int values of 3.98 and 1.14 μL/min/pmol CYP2J2, respectively (corresponding half-life values were 1.74 min and 6.06 min for terfenadine and astemizole respectively). For the newly identified CYP2J2 substrates,
Cl int values ranged from 0.06 to 0.49 μL/min/pmol CYP2J2 (Table 4) . Moreover, metabolism by CYP2J2 was confirmed by metabolite identification via mass spectral analysis.
Identification of Metabolites Generated from CYP3A4 and CYP2J2
Of the 139 compounds examined, six compounds, albendazole, amiodarone, astemizole, thioridazine, mesoridazine and danazol showed relatively rapid turnover in incubations with expressed CYP2J2. Since all compounds were also metabolized by CYP3A4, a study to assess similarities and differences in the metabolites formed by CYP3A4 and CYP2J2 was conducted. Figure 2 depicts the site of metabolism by CYP2J2 and CYP3A4. Figure 1A shows the extracted ion chromatograms of metabolites products of danazol have been previously detected in the human urine (Rosi et al., 1977) .
The mechanism of the oxidative cleavage of the isoxazole ring in danazol is unknown. Figure 1B shows the metabolic profiles of albendazole, amiodarone, astemizole, thioridazine, mesoridazine and danazol following incubation with recombinantly expressed CYP2J2 enzyme. All compounds produced metabolites that were observed in CYP3A4-mediated incubation mixtures of these compounds. As seen from the chromatograms however, the selectivity towards formation of these metabolites was quite different from that observed in CYP3A4 incubations. For albendazole, an additional metabolite was observed in the CYP2J2 containing incubation mixtures ( Figure 1B For both tamoxifen and cyclosporine, recombinant CYP2J2 and CYP3A4 formed one common metabolite while CYP3A4 formed two additional hydroxyl metabolites (Figure 2 ). The metabolism of nabumetone was also assessed by incubating the compound with recombinant CYP2J2 and CYP3A4. However, interpreting the mass spectral data was difficult for this compound due to poor ionization; but the metabolites were also observed by UV (data not shown).
Comparative Metabolism of Several Substrates in HLM and HIM
Thioridazine, mesoridazine, albendazole and amiodarone were incubated in human liver microsomes (HLM) and intestinal microsomes (HIM). The metabolic profiles were similar in the two biological matrices and the major metabolites mediated by CYP3A4 were observed (data not shown). Moreover, the predominant CYP2J2 mediated hydroxyl amiodarone metabolite was observed in both HLM and HIM but the unique CYP2J2 formed oxidative metabolite of albendazole was not detected probably due to its minor formation.
CYP Reaction Phenotyping of Danazol and Nabumetone
Many of the newly identified CYP2J2 compounds are also substrates for CYP3A4; however, information regarding the CYP mediated disposition of danazol and nabumethone in the literature is sparse. In this regard, CYP contribution towards the metabolism of danazol and nabumethone were investigated in HLM as greater number of active CYPs are represented in this system compared to HIM. The reaction phenotyping results in HLM showed that danazol is primarily a substrate for CYP3A4 (~86% contribution) and to a lesser extent CYP2D6 (~11% contribution) and nabumetone is a substrate for CYP1A2 (~ 50% contribution) and to a lesser extent CYP3A (Table 5 ). In addition to the danazol and nabumetone results, the results in Table 5 contain reaction phenotyping results for the other CYP2J2 substrates collected from the literature.
CYP2J2 and CYP3A4 Active Site Comparison
CYP2J2 homology model was built from multiple CYP2 crystal structures with no internal mutations and ligand free. The active site cavity for CYP2J2 and CYP3A4 are This article has not been copyedited and formatted. The final version may differ from this version. Figure 3A and C, respectively, and Figure 3B depicts an overlay of the two active sites. The cavity surfaces are rendered with mesh to highlight the differences in the actives site, with the caveat that CYP2J2 is an approximation given the lack of an authentic crystal structure. The homology model suggests that the active site volume for CYP2J2 is similar to that of CYP3A4, (1420 Å 3 vs. 1585Å 3 ) however the geometry is quite different (solvent occupied active site volumes calculated using software package Voidoo (Uppsala University, Biomedical Centre, Uppsala, Sweden). It is anticipated that CYP2J2 is more constrained near the heme prosthetic group compared to CYP3A4. The constraint arises due to the truncation of ß-4 and the loop preceding the truncated sheet protrudes into the active site. The distance across the active site above the heme from the I helix to either the loop preceding the truncated ß-4 (from Ala277 to Val346) in CYP2J2 is 9.4 Å while the distance in from the I helix to ß-4 in CYP3A4
(from Ala305 to Glu374) is 15.1Å . For many of the newly identified substrates there is broad overlap in metabolism by CYP3A4 and CYP2J2. A single site of metabolism by CYP2J2 was observed for several of the compounds like cyclosporine, tamoxifen, thioridazine and mesoridazine while CYP3A4 appeared to metabolize these substrates at multiple sites.
N-Desethyl Amiodarone Kinetics
The apparent kinetic parameters of N-desethyl amiodarone were determined in The Michaelis-Menten derived intrinsic clearance (Cl INT = V max / K m ) of N-desethyl amiodarone was 4.6 fold greater in HLM than that observed in HIM (Table 6A ). The kinetic parameters for recombinant enzymes CYP3A4 and CYP2J2 are shown in Table   6B ). Recombinant CYP3A4 Cl INT was 17 fold greater than that observed in recombinant
CYP2J2. An authentic standard of the hydroxyl amiodarone metabolite was not available; however, a K m of 10.3 μM was obtained for rCYP2J2 and is within the range observed in HLM and HIM (Table 6C) .
Albendazole S-Oxidation Kinetics
The Michaelis-Menten kinetic parameters of the S-oxide metabolite of albendazole were determined at a fixed reaction time (derived from a preliminary study Table 7 . The K i value was 3 to 11 fold greater than the K m value in the three enzyme systems.
Discussion
The overall role of CYP2J2 in drug metabolism has not been determined to date.
Several antihistamine drugs including terfenadine, ebastine and astemizole, have been identified as good substrates for CYP2J2, a CYP isoform predominately expressed in the intestine and heart tissues, with low levels in the liver (Delozier et al., 2007) . The extrahepatic contribution of CYP2J2 may contribute and result in higher than expected in vivo clearances than anticipated from in vitro liver microsome evaluations. To investigate CYP2J2's substrate diversity and overall role in drug metabolism, 139 marketed drugs, from different therapeutic classes, were screened as potential substrates for CYP2J2. From the compounds screened (Table 1) , eight novel structures were identified as substrates for CYP2J2. Moreover, these substrates were confirmed by mass spectral metabolite identification.
The CYP2J2 substrates showed in vitro Cl int values ranging from 0.06 to 0.49 μL/min/pmol CYP2J2 (or in vitro t 1/2 ranging from 14 to 120 min). These substrates as shown in Figure 2 belong to different therapeutic classes and vary in topology from relatively rigid structures such as amiodarone to large, more complex structures such as cyclosporine. However, compared to the anti-histamine substrates, terfenadine and astemizole, the new substrates have appreciably lower Cl int values, indicating a lower rate of metabolism. The limitations in using the substrate depletion method to identify potential CYP2J2 substrates lie in the inability to detect slowly metabolized compounds due to loss of protein activity and difficulty to ascertain true metabolism from experimental noise. As an example, diclofenac was evaluated in our study in which the loss of parent compound was not appreciable and not flagged as a substrate for CYP2J2
This article has not been copyedited and formatted. The final version may differ from this version. however, Lee et al., (Lee et al., 2005) identified it to be a substrate when they examined metabolite formation. In the studies presented herein, metabolite identification served mainly to confirm metabolism by CYP2J2. Despite the challenges of the screening methodology, several structural diverse compounds were identified. The intent of this work was not to identify all potential CYP2J2 substrates from our list of 139 compounds as we recognize some low clearance compounds may have been missed.
The broad structural diversity of newly identified substrates, which include cyclosporine, suggests that the active site volume of CYP2J2 may be large, similar to CYP3A4 and CYP2C8 (Johnson and Stout, 2005) . In fact, a strong overlap in substrate recognition by CYP2J2 and CYP3A4 was observed among all the newly identified CYP2J2 substrates. While the CYP2J2 model shown herein is a homology model built from the crystal structures of several CYP2 family members, it is still insightful to postulate how CYP2J2 is restrictive in its metabolism of large bulkier substrates like tamoxifen, thioridazine, mesoridazine and cyclosporine. Unlike the homology model of Li et al., (Li et al., 2008) which was built using the crystal structure of CYP2C9
containing internal mutations and a ligand bound to the active site, the homology model presented herein was based on a number of CYP2 family members, with no internal mutations and free of bound substrate. Examining the structure of CYP2J2's active site, ß-4 is truncated and the loop preceding the truncated sheet protrudes into the active site which limits access to the heme iron for oxidation. CYP2J2 has a more cylinder shape and is narrower than CYP3A4 near the heme iron which probably limits CYP2J2 to metabolize moieties that can extend closer towards the active heme iron. This restricted access and mobility around the heme iron may explain the greater selectivity of single site mediated CYP2J2 metabolism observed for cyclosporine, tamoxifen, thioridazine and mesoridazine while CYP3A4 appears to metabolize these substrates at multiple sites due to the ability of these compounds to rotate more freely in the active site.
CYP2J2 forms a unique metabolite with albendazole and the hydroxylated metabolite of amiodarone is formed predominately by CYP2J2 as only trace amounts were produced by CYP3A4. In the case of danazol, incubations with CYP2J2 formed only a single metabolite in contrast to several metabolites formed by CYP3A4. Danazol may enter the active site through the substrate access channel bound by helices A and F' and ß-sheet 1 and is metabolized only when the isoxazole ring approaches the heme iron forming a metabolite that is 3 amu greater than the molecular ion of the parent compound. The odd molecular ion suggests a possible loss of nitrogen atom. If the nitrile portion of the structure approaches the heme, inhibition will likely occur as observed by Jones et al., (Jones, 2008) .
Two substrates were chosen for extensive kinetic analysis to determine differences between CYP2J2 and CYP3A4 in HLM and HIM as the mRNA levels of CYP2J2 are fairly high in the intestine (Bieche et al., 2007) . The Michaelis-Menten derived intrinsic clearance (Cl INT ) values observed for N-desethyl amiodarone in HLM and HIM reflect differences in V max values. The V max disparity are likely attributed to the contribution of CYP2C8 in HLM which is present at lower levels in the intestine (Ohyama et al., 2000; Bieche et al., 2007) (Paine et al., 2006) . A comparison of recombinant CYP3A4 and CYP2J2 N-desethyl amiodarone activities showed a 17-fold difference due to a significantly greater V max contribution. Although, the authentic standard for the unique hydroxyl metabolite of amiodarone was not available, the K m of DMD30270 the hydroxylated metabolite were similar in the three systems (HLM, HIM, recombinant CYP2J2), ranging from 5.11 to 14.9 μM. Plasma concentrations of amiodarone range from 0.65 to 5.7 μM in patients (Staubli et al., 1983) and intestinal levels are likely to be higher than plasma levels. Although, the contribution of CYP2J2 relative to CYP3A4 and CYP2C8 in HIM and HLM is minor, it may become more important in amiodarone metabolism if these two CYPs are inhibited.
In the systems evaluated, HLM, recombinant CYP3A4 and recombinant CYP2J2, the metabolism of albendazole exhibits either substrate or product inhibition kinetics.
The rate of albendazole S-oxidation decreased when substrate concentrations exceeded 10 μM in HLM and recombinant CYP2J2. For recombinant CYP3A4, the metabolism decreased when concentrations exceeded 20 μM however, the decrease in velocity was not as pronounced as that observed in HLM and recombinant CYP2J2. Inhibition of enzyme activity at high concentration is one of the most common deviation from typical Michaelis-Menten kinetics (Lin et al., 2001 ). In the analysis of albendazole S-oxidation kinetic data, a two site inhibition model containing sites for metabolism and inhibition (Lin et al., 2001 ) best modeled the kinetic data. In all systems, the K s was similar but the inhibition constant, K i , was found to be 3 to 10 times greater than the K s indicating that the inhibitory site has a weaker affinity for the substrate than the catalytic site. The which may act as a noncompetitive inhibitor, cannot be ruled out as albendazole Soxidation profile will look similar to a substrate inhibition profile.
In drug discovery research, a compound's susceptibility to metabolism is commonly evaluated using human liver microsomes. Low turnover compounds from HLM evaluations are then progressed forward for in vitro and in vivo evaluation in rodents mainly to gain insight of ADME properties of the new drug candidate or insight for a chemical series. Despite low metabolism observed with human and animal liver microsomes, the compound dosed in vivo may give a systemic clearance value greater than hepatic blood flow indicating extrahepatic metabolism and/or involvement of nonhepatic route of clearance. With the identification that CYP2J2 metabolizes structurally diverse substrates, this isoform may contribute to total systemic clearance previously unaccounted especially in the intestine and heart. Hashizume et al., (Hashizume et al., 2002) showed that although CYP3A4 may be responsible for hepatic metabolism of ebastine, intestinal metabolism and first pass appears to be CYP2J2 mediated. Moreover, CYP2J2 has been identified as the major contributor to the first pass metabolism of astemizole (Hashizume et al., 2002; Matsumoto et al., 2002) . It is quite possible that for many of these drugs metabolized by both CYP2J2 and CYP3A4, where CYP3A4 is implicated in both intestinal and hepatic metabolism, the contribution of CYP2J2 in the intestine may have been overlooked and the contribution by heart is unclear at this time.
Additionally, the clinical significance of CYP2J2 in the liver is minor given the large abundance of CYP3A4; while the abundance of CYP2J2 is greater in non hepatic tissues such as heart and intestine warranting further assessment to determine its clinical significance.
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In summary, eight new structurally diverse substrates for CYP2J2 metabolism were discovered among 139 substrates evaluated. The substrates belong to different therapeutic classes and vary in shape from relatively small rigid structures such as amiodarone to larger more complex structures such as cyclosporine. There is a strong overlap in substrate recognition by CYP2J2 and CYP3A4, and the active site of CYP2J2 although similar in size to CYP3A4 is more restrictive in that many of the substrates are metabolized at a single site. Among the newly identified substrates, albendazole forms a unique CYP2J2 mediated metabolites. While our findings demonstrate the ability of CYP2J2 to metabolize structurally diverse compounds, the clinical significance is likely overshadowed by CYP3A4 suggesting a minor role in overall intestine and liver metabolism.
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